Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01723774 · ClinicalTrials.gov registry record · Phase 2
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
A Phase 2 study of Breast Neoplasms, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 4
- Study locations
NCT01723774 is a Phase 2 study of Breast Neoplasms that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 84 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01723774, a Phase 2 study of Breast Neoplasms, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2) result in fewer patients with on therapy Ki67\>10% compared to historical control.
Conditions Studied
Interventions
- DRUG Anastrozole
- DRUG Goserelin
- PROCEDURE Tumor biopsy
- DRUG PD0332991
- PROCEDURE Surgery (standard of care)
Study Locations (4)
Alabama
- University of Alabama - Birmingham
Arizona
- Mayo Clinic - Scottsdale - Scottsdale
Minnesota
- Mayo Clinic - Rochester - Rochester
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2013-04-10 |
| Est. Completion | 2026-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01723774
The ClinicalTrials.gov registry entry for NCT01723774 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (85% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Anastrozole is the first listed.
NCT01723774 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01723774 about?
NCT01723774 is a clinical study titled "PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer". A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate wh...
What is the current status of trial NCT01723774?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2013-04-10. Estimated completion is 2026-08-24.
What conditions does trial NCT01723774 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT01723774?
The interventions under investigation include: Anastrozole (DRUG), Goserelin (DRUG), Tumor biopsy (PROCEDURE), PD0332991 (DRUG), Surgery (standard of care) (PROCEDURE).
Who is sponsoring clinical trial NCT01723774?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01723774 being conducted?
This trial has 4 study locations across Alabama, Arizona, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.